Shenfield G M, Hodson M E, Clarke S W, Paterson J W
Thorax. 1975 Aug;30(4):430-5. doi: 10.1136/thx.30.4.430.
Twelve patients with airways obstruction (due to asthma and/or chronic bronchitis) were given a trial of prednisone therapy to assess reversibility. Six asthmatic patients responded well but no predictive criteria were found. In three patients improvement in forced expiratory volume in 1 second (FEV1) was detectable at 6 hours but not at 3 hours. One patient took 36 hours to show any sign of improvement. None of the patients who improved reached their peak FEV1 before six days treatment with prednisone, which suggests that a 'trial of steroids' should last for at least one week. Potentiation, as measured by either a greater peak rise or a more sustained increase in FEV1 after isoprenaline, was observed in five of the six asthmatic patients responding to steroids. It is concluded that potentiation of catecholmines is one of the mechanisms by which corticosteroids may act in asthma.
12名患有气道阻塞(由哮喘和/或慢性支气管炎引起)的患者接受了泼尼松治疗试验,以评估可逆性。6名哮喘患者反应良好,但未发现预测标准。3名患者在6小时时可检测到1秒用力呼气量(FEV1)有所改善,但在3小时时未改善。1名患者在36小时后才出现任何改善迹象。在接受泼尼松治疗6天之前,没有一名改善的患者达到其FEV1峰值,这表明“类固醇试验”应持续至少一周。在对类固醇有反应的6名哮喘患者中的5名中,观察到通过异丙肾上腺素后FEV1的更大峰值上升或更持续增加来衡量的增强作用。得出的结论是,儿茶酚胺的增强作用是皮质类固醇在哮喘中发挥作用的机制之一。